Additionally, in 57.1% of these cases, HER3 was cluster-amplified profusely, presenting a putative therapeutic target for targeted therapy.<h4>Conclusion</h4>Our study serves as the initial basis for further investigation of the HER3 gene as a putative therapeutic target in liposarcoma. This evidence concerns the gene ERBB3 and liposarcoma.